KRas Pathway Assay Services

The small GTPase, KRas, is a known oncogene that is frequently mutated in a large percentage of cancers and is associated with poor disease prognosis. Mutated KRas is locked in the activated GTP bound state and facilitates enhanced Ras signaling in cancer cells. While being a desirable target, the absence of good druggable binding pockets has made modulator compound discovery challenging and unsuccessful.

The recent identification of a unique binding pocket and successful inhibition of the KRas G12C mutant by covalent chemical modifiers have led to the resurgence of interest in the design of inhibitors targeting KRas directly. Alternative efforts are undertaken at inhibition of interactions of KRas with exchange factors and effector proteins.

Reaction Biology provides a variety of services to discover new inhibitors targeting the KRAS pathway including:

  • Nucleotide exchange assay to monitor SOS mediated exchange of GDP to GTP
  • Direct binding assays via thermal shift or surface plasmon resonance techniques
  • HTRF assays for testing the disruption of protein:protein interactions of KRas with SOS or Raf proteins 
  • Activity assays for testing of kinase inhibitors
  • Recombinant proteins such as KRas, GEFs, GAP and others

The KRas Pathway

The KRas pathway can be inhibited by numerous compounds at different stages. The initial signaling can be inhibited with EGRF family inhibitors. KRas activation can be intercepted by inhibiting guanidin exchange factors such as SOS. KRas processing as well as KRas itself can be inhibited by siRNA or allele-specific RAS inhibitors. Finally, the two KRas downstream signaling pathways MAPK and PI3K signaling cascades can be inhibited at each kinase step.

summary of KRas pathway inhibitors

Assays for the discovery of KRas pathway inhibitors

KRas Protein-Protein Interaction Assay

KRas::SOS1

Disruption of SOS1 binding to KRas can be used as an orthogonal method for studying SOS1 specific compounds. The assay uses an HTRF-based detection of interaction.

KRas::cRAF

cRAF recognizes the GTP-bound form of KRas. cRAF binding assay can be used for the identification of disruptors of interaction between KRas and cRAF, as well as quantification of the nucleotide exchange reaction. This assay can be used as an alternative to the regular NEA with an optional examination of SOS1 independent GTP binding. The assay uses an HTRF-based detection of interaction.

The Protein-Protein Interaction assay is available for wild-type KRas and various KRas G12 mutants. Please inquire for custom-tailored assay development.

 

Nucleotide Exchange Assay

The Nucleotide Exchange Assay (NEA) allows the monitoring of SOS1/2 mediated exchange of fluorescently labeled GDP to GTP.

The main application of the assay is to identify compounds that lock KRas in the inactive “OFF” state by preventing GTP binding.

The Nucleotide Exchange Assay is available for KRas and various G12 mutants thereof. Please inquire for custom-tailored assay development.

Thermal Shift Direct Binding Assay

 

comparison of thermal shift assays of KRas bound to a variety of KRas inhibitors selective for G12C mutant

 

Thermal shift assays are used to assess the effects of compounds on protein stability. Selectivity of compounds ARS-1620 and AMG-510 for KRas mutant G12C is clearly shown among KRas wt and mutants. The melting temperature of KRas G12C incubated with ARS-1620 for example shifts from 53.8 degree celsius to 58.5 degree Celsius with a second peak appearing at 65.6 degree Celsius. The melting temperature of KRas G12C incubated with BI-2852, however, did not result in a significant shift showing that BI-2852 does not bind to KRas G12C.

summary of KRas inhibitors for selectivity for G12C

The Thermal Shift Assay is available for KRas and various G12 mutants thereoff as well as SOS1 and SOS2. Please inquire for custom-tailored assay development.

SPR Direct Binding Assay

Surface Plasmon Resonance (SPR) is used to quantify the binding affinity of the molecule as well as binding kinetics. A comparison between KRas WT and mutant proteins can be performed to determine selectivity.

KRas and various G12 mutants thereof as well as SOS1 are established for SPR analysis. Please inquire for custom-tailored assay development.

SPR is used to determine the binding specificty of KRpep-2D on KRas G12D mutant

comparison of KRpep-2d bound to KRas wild type and mutants with SPR

Example study: The KRas G12D mutant selective peptide KRpep-2d was used to show the difference in the binding of KRpep-2d to mutant G12D versus wild type KRas and other mutants. The peptide binds to all targets, however, the binding affinity (KD) of the peptide is 15 x higher when interacting with the G12D mutant.

KRAS-related Recombinant Proteins

recombinant KRas protein constructs with different tags, 6xHis, GST and biotin

At Reaction Biology, we have created three versions of wild-type KRas recombinant proteins, with 6xHis tag, GST tag, and 8xHis plus Biotin.

In addition, we offer KRas mutants G12C, G12D, and G12V. G13 mutant variants are in production.

Our KRas-related recombinant proteins are available for purchase, please inquire for more information.

 

recombinant constructs of SOS1, SOS2, RASA1 and cRAF were produced for KRas drug testing

 

A variety of KRas pathway related recombinant proteins were produced in house and are available for screening.